INTRODUCTION {#s1}
============

Cancer is a major public health problem worldwide, with overall death rates that rose during most of the 20 th century. In the United States, cancer is the second leading cause of death \[[@R1]\]. In China, cancers are the leading cause of death, despite the development of effective drugs and supportive care \[[@R2]\].

Long noncoding RNAs (lncRNAs) are non-protein-coding molecules, longer than 200 nucleotides \[[@R3]\]. Many studies have reported that lncRNAs are deregulated in cancers, suggesting that the aberrant expression of lncRNAs is associated with tumorigenesis, metastasis, and prognosis in cancer.

Human *UCA1* (urothelial carcinoma associated 1) is a lncRNA that was first identified in human bladder carcinoma \[[@R4]\], and whose oncogenic effect may be related to glucose metabolism \[[@R5]\]. Recently, some studies have reported the relevance of *UCA1* in cancer prognosis and the acquired resistance to drugs \[[@R6]--[@R17]\]. For example, patients with advanced non-small cell lung cancer (NSCLC) that harbor mutations that activate epidermal growth factor receptor (*EGFR*) can be treated with *EGFR*-tyrosine kinase inhibitors (TKIs) such as gefitinib. However resistance to this treatment is often acquired, most commonly via a secondary *T790M* mutation. Cheng et al. found that the lncRNA *UCA1* was upregulated in resistant cells, and that overexpression of *UCA1 was associated with shorter* progression-free survival (PFS) in non-resistant cells \[[@R8]\]. Furthermore, *UCA1* knockdown restored sensitivity to gefitinib in acquired-resistant NSCLC cells without the *T790M* mutation, and inhibited the activation of the AKT/mTOR pathway and epithelial-mesenchymal transition.

No meta-analysis was been conducted to assess the association between *UCA1* and the survival of patients with cancers. Therefore, this meta-analysis investigated an association between *UCA1* and the survival of cancer patients. Overall survival (OS) and PFS were the primary endpoints.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The initial search of the databases produced 53 studies (Figure [1](#F1){ref-type="fig"}). After excluding duplicate articles, 49 potentially eligible studies were selected. After a detailed evaluation, 12 studies were selected for the final meta-analysis with a total of 954 cancer patients (Table [1](#T1){ref-type="table"}). Of the 12 studies, 2, 3, 2, and 2 concerned colorectal cancer, NSCLC, ovarian cancer, and gastric cancer, respectively, and there was one study each regarding esophageal squamous cell carcinoma and hepatocellular carcinoma.
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###### Characteristics of the included studies[^a^](#tfn_001){ref-type="table-fn"}

  First author   Year   n[^b^](#tfn_002){ref-type="table-fn"}   Age[^c^](#tfn_003){ref-type="table-fn"}   Men, %   Reference   FU, mo   Cancer   Outcome   Co-variants                                                                                NOS
  -------------- ------ --------------------------------------- ----------------------------------------- -------- ----------- -------- -------- --------- ------------------------------------------------------------------------------------------ -----
  Cheng          2015   94                                      NA\*                                      46.4     GAPDH       24       NSCLC    PFS       Age                                                                                        7
  Gao            2015   20                                      NA                                        NA       GAPDH       NA       GC       OS        Lymph node; clinical stage                                                                 8
  Han            2014   80                                      55                                        49       GAPDH       42.6     CRC      OS        NA                                                                                         8
  Kamel          2015   82                                      57                                        68.3     GAPDH       NA       HCC      PFS       Barcelona clinic liver Cancer stage;Child score; mean tumor size                           8
  Li             2014   90                                      60                                        55.6     GAPDH       43       ESCC     OS        Differentiation grade; lymph node; clinical stage                                          7
  Ni             2015   54                                      NA                                        72.2     GAPDH       NA       CRC      OS        Lymphatic invasion; lymph node; distant metastasis; clinical stage                         8
  Nie            2015   112                                     63.2                                      59.8     GAPDH       45       NSCLC    OS        Lymph node; clinical stage                                                                 8
  Tao            2015   80                                      65.1                                      60       RUN6        NA       CRC      OS        Lymph node; clinical stage                                                                 7
  Wang           2015   60                                      NA                                        61.7     GAPDH       NA       NSCLC    OS        Lymph node; clinical stage                                                                 7
  Yang           2016   53                                      NA                                        0        GAPDH       NA       Ovary    OS        Lymph node                                                                                 8
  Zhang          2016   117                                     33                                        0        RUN6        22       Ovary    OS        Chemotherapy response; lymph node; clinical stage                                          8
  Zheng          2015   112                                     NA                                        57.1     GAPDH       NA       GC       OS, PFS   Tumor size; invasion depth; lymphatic metastasis; invade adjacent organs; clinical stage   8

This study characterized patients as \> 65 or \< 65; technique used to quantify *UCA1* was real-time PCR in all studies;

sample size;

median age, y.

CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; FU, follow-up; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GC, gastric cancer; HCC, hepatocellular carcinoma; NA, not available.

Not all studies examined both OS and PFS, because most of the studies were retrospective cohort studies; 10 studies investigated the association between *UCA1* and OS, while 3 studies assessed the association between *UCA1* and PFS.

Results of the meta-analysis {#s2_2}
----------------------------

The association between the expression of *UCA1* and OS was investigated in 10 studies (Figure [2](#F2){ref-type="fig"}). We found a statistically significant negative association between levels of *UCA1* and OS (HR = 1.81, 95% CI = 1.52--2.17). In a subgroup analysis of cancer sites, significant negative associations were found between levels of *UCA1* and OS in the following cancers: colorectal (HR2.61, 95% CI1.56--4.37), NSCLC (HR1.49, 95% CI1.16-1.90), gastric cancer (HR2.19, 95% CI1.36--3.51), and ovarian cancer (HR1.89, 95% CI1.14--3.12). When the studies that adjusted for lymph node and clinical stage were included, shorter OS was also observed (HR1.71, 95% CI = 1.42--2.07). We did not perform subgroup analyses for esophageal squamous cell carcinoma or hepatocellular carcinoma, because no more than one study each investigated these associations between *UCA1* and OS.
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The association between *UCA1* and PFS was investigated in 3 studies (Figure [3](#F3){ref-type="fig"}). There was a significant negative association between *UCA1* levels and PFS (HR2.59, 95% CI1.61--4.16; Figure [3](#F3){ref-type="fig"}). All the results are listed in the Table [2](#T2){ref-type="table"}.
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###### Results of this meta-analysis

                                                   HR (95% CI)         *P*          I^2^ (%)   *P*
  ---------------------------------------- ------- ------------------- ------------ ---------- ------
  Overall survival                                 1.81 (1.52--2.17)   \< 0.00001   19         0.27
  Site of cancer                           CRC     2.62 (1.56--4.37)   0.0002       0          0.46
                                           NSCLC   1.49 (1.16--1.90)   0.001        0          0.34
                                           GC      2.19 (1.36--3.51)   0.001        0          0.75
                                           Ovary   1.89 (1.14--3.12)   0.01         51         0.15
  Adjusted lymph node and clinical stage           1.71 (1.42--2.07)   \< 0.00001   0          0.43
  Progression-free survival                        2.59 (1.61--4.16)   \< 0.00001   0          0.86

CRC, colorectal cancer; NSCLC, non-small cell lung cancer; GC, gastric cancer.

DISCUSSION {#s3}
==========

This is the first meta-analysis to evaluate the association between *UCA1* levels and cancer prognosis. We found that increased levels of *UCA1* were significantly associated with shorter OS and PFS times in cancer patients. In the subgroup analyses, *UCA1* levels were significantly and negatively associated with OS times in colorectal cancer, NSCLC, ovarian cancer, and gastric cancer.

*UCA1* putatively influences the proliferation, apoptosis, and cell cycle progression of colorectal cancer cells \[[@R6]\]. Ni et al. \[[@R11]\]also found that knockdown of *UCA1* was associated with suppressed cell proliferation and metastasis in colorectal cancer cells. Nie et al. \[[@R12]\] suggested that silencing of *UCA1* impaired the proliferation and colony formation of NSCLC cells. Wang and coworkers \[[@R13]\] found that *UCA1* levels were associated with histological grade and lymph node metastasis in NSCLC. In addition, a clinicopathologic analysis revealed that *UCA1* levels correlated with worse differentiation, greater tumor size and invasion depth, and TNM stage in gastric cancer \[[@R14]\]. Thus, these data might explain why high levels of *UCA1* were significantly associated with shorter OS and PFS in cancer patients in this meta-analysis.

The clinical implications of *UCA1* in various cancers have not been studied well. Wang et al. \[[@R4]\] showed that a *UCA1* assay was highly specific (91.8%, 78 of 85) and very sensitive (80.9%, 76 of 94) in the diagnosis of bladder cancer. However, Milowich et al. \[[@R18]\] indicated that the efficiency of the *UCA1* test for detecting primary and recurring bladder cancer was low. Future studies should focus on the clinical utility of *UCA1*-based cancer diagnosis in clinical trials. In addition, *UCA1* has been implicated in the acquired resistance to EGFR-TKIs in EGFR-mutant NSCLC that did not include a *T790M* mutation \[[@R8]\]. Thus, the expression of *UCA1* should be evaluated before patients receive EGFR-TKIs.

Some limitations of this meta-analysis should be pointed out. Firstly, the number of included studies in our meta-analysis was moderate. Secondly, most of the studies were conducted with Chinese sample populations and, therefore, our results may be applicable only to this ethnic group. Thirdly, not all of the studies reported the cutoff values of *UCA1*. Finally, many factors, such as gender and chemotherapy, may also affect OS and PFS. Thus, the results of this meta-analysis should be confirmed in future studies.

In conclusion, the results of this meta-analysis suggest that *UCA1* may be a risk factor for shorter OS and PFS in cancers. Well-designed studies with large sample sizes are needed to confirm further the association between *UCA1* and clinical outcomes of cancers in various ethnic populations.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

We searched the databases PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI) and Wanfang, to 14 March 2016, for relevant articles. The search terms used were "*UCA1*" and "cancer or carcinoma or tumor". Reference lists of relevant articles were also reviewed to identify potential eligible studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

For inclusion in this meta-analysis, the studies met the following criteria: cohort design; investigated the association between *UCA1* and cancer prognosis (OS or PFS); and sufficient original data for calculating a hazard ratio (HR) with its 95% confidence interval (CI). A study was excluded if it was not relevant to cancer, *UCA1*, or cancer prognosis; involved animals; or was an editorial, review, or abstract. If more than one study used the same patient cases, the one with the most comprehensive population was included. Differences in opinion among the authors were solved by discussion.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two investigators extracted and reviewed the data independently. The following data were extracted: the first author\'s name, year of publication, patient ages and genders, duration of follow-up, sample size, site of cancer, PFS, OS, and co-variants. Since all included studies were cohort studies, the Newcastle-Ottawa Scale (NOS) was used to evaluate the methodological quality \[[@R19]\].

Statistical analysis {#s4_4}
--------------------

The strength of association between *UCA1* and cancer prognosis (PFS and OS) was assessed by computing the HR with its corresponding 95% CI. OS was defined as the time between diagnosis and death. PFS was defined as the time between diagnosis and progression. The heterogeneity among eligible studies was checked by using the chi-squared based *Q*-statistic test. The random-effects model or fixed-effects model was used to analyze the pooled HRs. If the number of included studies in an analysis was more than 10, Egger\'s linear regression test and Begg\'s funnel-plot analysis were used to weigh the potential publication bias. All the *P*-values were determined by a 2-sided test. All statistical analyses were conducted using STATA software (version 12.0; Stata, College Station, Texas).
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